- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.08. | HeartBeam schließt Aktienverkaufsvereinbarung über 25 Millionen US-Dollar mit Titan Partners | 2 | Investing.com Deutsch | ||
| 14.08. | HeartBeam, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.08. | HeartBeam Q2 slides show clinical progress despite wider Q2 2026 loss | 2 | Investing.com | ||
| 13.08. | HeartBeam Reports Q2 2026 Results: Full Earnings Call Transcript | 1 | Benzinga.com | ||
| 13.08. | Heartbeam Aktie: Quartalsverlust belastet nachbörslichen Kurs | 1 | Investing.com Deutsch | ||
| 14.07. | HeartBeam receives patent for multi-modal cardiac sensing device | 1 | Investing.com | ||
| HEARTBEAM Aktie jetzt für 0€ handeln | |||||
| 02.07. | HeartBeam, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.06. | HeartBeam, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 22.05. | H.C. Wainwright cuts Heartbeam stock price target on slower sales ramp | 1 | Investing.com | ||
| 15.05. | Benchmark cuts Heartbeam stock price target on dilution to $5 | 1 | Investing.com | ||
| 13.05. | Earnings Call: HeartBeam übertrifft EPS-Prognose für Q1 2026 - Aktie legt nachbörslich zu | 2 | Investing.com Deutsch | ||
| 13.05. | HeartBeam Q1 2026 Earnings Call: Complete Transcript | 4 | Benzinga.com | ||
| 13.05. | HeartBeam GAAP EPS of -$0.12 beats by $0.02 | 1 | Seeking Alpha | ||
| 13.05. | HeartBeam, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.05. | HeartBeam starts pilot study of on-demand 12-lead ECG patch | - | MassDevice | ||
| 24.04. | HeartBeam (BEAT): 10 Best NASDAQ Growth Stocks to Buy and Hold Forever | 16 | Insider Monkey | ||
| 20.04. | Heartbeam: D. Boral Capital stuft Aktie wegen Konditionen der Kapitalerhöhung herab | 16 | Investing.com Deutsch | ||
| 20.04. | D. Boral Capital cuts Heartbeam stock rating on capital raise terms | 1 | Investing.com | ||
| 16.04. | HeartBeam closes $10M public offering for product rollout | 1 | Investing.com | ||
| 16.04. | HeartBeam, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 12,120 | -0,90 % | Eckert&Ziegler-Aktie im Check am 19.09. (10:40 Uhr): Meine aktuelle Lageeinschätzung | ||
| UNITEDHEALTH | 328,40 | +0,06 % | Dividendenbekanntmachungen (14.09.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) BROOKFIELD CORPORATION CA11271J1075 0,07 USD 0,0603 EUR BROOKFIELD WEALTH SOLUTIONS LTD BMG174341047 0,07 USD 0,0603 EUR CALAMOS... ► Artikel lesen | |
| TELADOC HEALTH | 5,460 | -0,36 % | Teladoc Health, Inc.: Teladoc Health Appoints Financial Executive Mark Anquillare to Its Board of Directors | NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced the appointment of Mark V. Anquillare to its board of directors. Mr. Anquillare... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,068 | +5,26 % | Sernova Biotherapeutics Inc: Sernova shareholder Sangha to vote "yes" in takeover | ||
| DEXCOM | 77,60 | -0,26 % | Dexcom's CFO Jereme Sylvain To Take Addl. Role Of COO | WASHINGTON (dpa-AFX) - DexCom Inc. (DXCM), a medical device company, announced the promotion of Jereme Sylvain to the role of Chief Operating Officer in addition to his duties as Chief Financial... ► Artikel lesen | |
| CERENOME | 1,744 | -0,57 % | Cerenome, Inc.: Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division | HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), today announces the appointment of Samantha... ► Artikel lesen | |
| RESMED | 201,60 | +2,88 % | ResMed Inc. (RMD)'s Sleep Apnea Leadership Supports Growth Despite Rising Competitive Pressures | ||
| ATOSSA THERAPEUTICS | 2,060 | +5,10 % | ATOSSA THERAPEUTICS, INC. - 8-K, Current Report | ||
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals: Historischer Wendepunkt - darum fliegt die Aktie! | Volltreffer: Bereits im Frühjahr hatte ich die positive Entwicklung bei Sonoma Pharmaceuticals antizipiert und die Nano-Cap-Aktie als hochinteressante Turnaround-Spekulation vorgestellt. Damals hatte... ► Artikel lesen | |
| TANDEM DIABETES | 14,900 | +1,36 % | Tandem Diabetes Care, Inc.: Tandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility with Abbott FreeStyle Libre 3 Plus Sensor in Five International Markets | Compatibility now available in five countries, with additional markets expected throughout 2026.Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company... ► Artikel lesen | |
| CO-DIAGNOSTICS | 0,970 | +2,57 % | Co-Diagnostics, Inc. - 8-K, Current Report | ||
| QUIDELORTHO | 9,076 | -1,99 % | QuidelOrtho Corporation: QuidelOrtho Reports Second Quarter 2026 Financial Results | ? Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth ?
? Excluding China, total revenue grew 6% both as... ► Artikel lesen | |
| VERU | 2,395 | -0,62 % | Veru Inc.: Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress | -- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients - -- Phase 2b PLATEAU clinical trial interim analysis and... ► Artikel lesen | |
| LIFEWARD | 7,030 | -1,82 % | Lifeward legt Termin für jährliche und außerordentliche Hauptversammlung 2026 fest | ||
| CLOVER HEALTH INVESTMENTS | 3,920 | +1,03 % | Clover Health Investments, Corp.: Clover Health Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for Full Fiscal Year 2026 | WILMINGTON, Del., April 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) ("Clover" or the "Company"), a physician enablement company committed to bringing access to great... ► Artikel lesen |
Das Unternehmen HEARTBEAM INC kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,008 (+2,01 %) liegt der Kurs bei 0,411 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HEARTBEAM INC finden Sie auf Wallstreet Online.